SCHEMBL16631648

SCHEMBL16631648

O=c1nc2[nH]c(=O)c(F)cn2cc1[C@@H]1O[C@H](CO)C(O)[C@@H]1O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.38
GMNN O75496 1/20 0.38
MAPT P10636 1/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
NFKB1 P19838 1/20 0.38
STAT6 P42226 1/20 0.38
HIF1A Q16665 1/20 0.38
SLC5A2 P31639 2/20 0.38
PNP P00491 3/20 0.37
PYGM P11217 3/20 0.36
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16631645 0.89 LMNA (0.39) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631489 0.87 KDM4E (0.38) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631332 0.84 LMNA (0.47) LMNASMN1; SMN2MAPTPMP22TSHR
SCHEMBL16631644 0.81 PNP (0.36) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631442 0.81 SLC28A1 (0.46) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL18080271 0.80 P2RY2 (0.49)
SCHEMBL16631702 0.80 PNP (0.35) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631646 0.80 PNP (0.35) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631441 0.77 PYGM (0.38) LMNASMN1; SMN2KDM4EGMNNMAPT
SCHEMBL16631485 0.77 KDM4E (0.40) LMNASMN1; SMN2KDM4EGMNNMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 US disclosed
WO-2015051173-A2 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 LMNA 776/4885SMN1; SMN2 263/4885KDM4E 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.